Skip to content

Shares (Diluted) at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
197.7M+0.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
60.2M+11.3%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
31.5M+17.3%
XER
Xeris Biopharma Holdings, Inc.XERS
177.6M+16.5%
PVL
Palvella TherapeuticsPVLA
13.1M+18.8%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
172.7M+3.0%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$132.59M-86.9%

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's shares (diluted)?
Polaryx Therapeutics, Inc. (PLYX) reported shares (diluted) of 47.2M in Q1 2026.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.